**Simon P. Weisenhorn**

simonweisenhorn@gmail.com | (704) 666-0010 | www.linkedin.com/in/simon-weisenhorn-stat

|  |
| --- |
| **EDUCATION** |

**North Carolina State University** – Raleigh, NC August 2023

*Master of Statistics*

* GPA: 3.33
* Relevant Coursework: Statistical Principles of Clinical Trials, Applied Multivariate and Longitudinal Data Analysis, Statistical Programming, Advanced Statistical Programming, Fundamentals of Statistical Theory I, Fundamentals of Statistical Theory II, Applied Statistical Methods, Fundamentals of Linear Models and Regression, Data Science for Statisticians, and Statistical Practice

**University of North Carolina at Chapel Hill** – Chapel Hill, NC May 2022

*B.S., Statistics and Analytics*

*Data Science Minor*

* GPA: 3.485
* Relevant Coursework: Advanced Methods of Data Analysis, Data Science, Stochastic Modeling, Probability, Optimization, Linear Algebra, and Multiple Variable Calculus

|  |
| --- |
| **EXPERIENCE** |

**Catalyst Clinical Research** – Raleigh, NC                                    May 2020 – August 2022 (Summers) *Biostatistician Intern; Contract research organization providing multi-therapeutic resourcing and cancer therapies*

* Assisted lead project statistician in several different clinical trials including:
  + A Proof-of-Concept, Open-Label Study, Evaluating the Safety and Tolerability of Cilofexorin in Subjects with Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
    - Validated study listings using SAS version 9.4 on a Windows based platform
    - Reprogrammed listings for an independent validation
  + A Phase II Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults. This NIH adaptive trial aims to streamline the pathway to finding urgently needed COVID-19 treatments by repurposing either licensed or late-stage-development medicines and testing them in a way that identifies the most promising agents for a Phase III study in the most expedient way possible.
  + A Prospective, Open-Label, Dose-Escalation Phase I Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate for the Treatment of Knee Osteoarthritis
  + A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Drug in Infants and Young Children with Achondroplasia
    - Annotated all of the case report form documents for the programmers to reference
  + A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of a New Drug in Subjects with Select Advanced Solid Tumors Who Have Received up to Five Lines of Prior Therapies
    - Addressed client comments on outputs and dataset programs
* Read and conformed with Catalyst Standard Operating Procedures (SOPs)
* Programmed listings and tables from CDISC (Clinical Data Interchange Standards Consortium) data sets including both SDTM (Study Data Tabulation Model) and ADaM (Analysis Dataset Model)

**North Carolina State University** – Raleigh, NC                                    August 2022 – May 2023

*Graduate Teaching Assistant*

* Instructed four sections of Introduction to Statistical Programming under Dr. Justin Post
* Met with 150 students each week to teach the basics of how to program in SAS
* Hosted office hours to assist students outside of class for three hours per week
* Single-handedly graded every student’s homework assigments, quizzes, and final projects
* Communicated with students via email regarding questions and updates
* Supervised different learning management software such as Moodle and Yellowdig

|  |
| --- |
| **ADDITIONAL INFORMATION** |

* Proficient in R and SAS
* Familiar with Python, Java, CSS, and HTML
* Interests: Backpacking, Fishing, Running, and Traveling